康哲药业(00867.HK)：抗急性缺血性卒中1类新药注射用Y-3中国上市许可申请已获受理

Core Viewpoint - Kangzheng Pharmaceutical (00867.HK) has received acceptance for its New Drug Application (NDA) for the injection Y-3, a brain cell protective agent intended for acute ischemic stroke, from the National Medical Products Administration (NMPA) of China on December 11, 2025 [1] Group 1 - The product Y-3 is classified as a Class 1 new drug [1] - The intended use of Y-3 is for the protection of brain cells in cases of acute ischemic stroke [1] - The NDA acceptance marks a significant step in the product's development and potential market entry [1]